Insulin-like growth factors and neoplasia

被引:1139
作者
Pollak, MN
Schernhammer, ES
Hankinson, SE
机构
[1] McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada
[2] Lady Davis Res Inst, Montreal, PQ H3T 1E2, Canada
[3] Harvard Univ, Channing Lab, Boston, MA 02115 USA
[4] Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA
关键词
D O I
10.1038/nrc1387
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The insulin-like growth factor 1 (IGF1) signalling pathway has important roles in regulating cellular proliferation and apoptosis. Converging results from epidemiological research and in vivo carcinogenesis models indicate that high levels of circulating IGF1 are associated with increased risk of several common cancers. Ongoing research seeks to clarify the mechanisms underlying these observations and to determine the extent to which IGF physiology influences patterns of cancer incidence. Various therapeutic strategies that target the IGF1 receptor have demonstrated impressive antineoplastic activity in laboratory models, and clinical trials of several novel drug candidates are planned.
引用
收藏
页码:505 / 518
页数:14
相关论文
共 168 条
[1]   IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation [J].
Abuzzahab, MJ ;
Schneider, A ;
Goddard, A ;
Grigorescu, F ;
Lautier, C ;
Keller, E ;
Kiess, W ;
Klammt, J ;
Kratzsch, J ;
Osgood, D ;
Pfäffle, R ;
Raile, K ;
Seidel, B ;
Smith, RJ ;
Chernausek, SD ;
Frank, GR ;
Kaplowitz, PB ;
Pescovitz, OH ;
Smith, EP .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (23) :2211-2222
[2]   Serum IGF-I and IGFBP-3 in healthy pregnancies and patients with preeclampsia [J].
Altinkaynak, K ;
Aksoy, H ;
Bakan, E ;
Kumtepe, Y .
CLINICAL BIOCHEMISTRY, 2003, 36 (03) :221-223
[3]   Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy [J].
Amling, CL ;
Riffenburgh, RH ;
Sun, L ;
Moul, JW ;
Lance, RS ;
Kusuda, L ;
Sexton, WJ ;
Soderdahl, DW ;
Donahue, TF ;
Foley, JP ;
Chung, AK ;
McLeod, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :439-445
[4]   Healthy animals with extreme longevity [J].
Arantes-Oliveira, N ;
Berman, JR ;
Kenyon, C .
SCIENCE, 2003, 302 (5645) :611-611
[5]   H19 and Igf2 -: enhancing the confusion? [J].
Arney, KL .
TRENDS IN GENETICS, 2003, 19 (01) :17-23
[6]   BLOCKADE OF THE TYPE-I SOMATOMEDIN RECEPTOR INHIBITS GROWTH OF HUMAN-BREAST CANCER-CELLS IN ATHYMIC MICE [J].
ARTEAGA, CL ;
KITTEN, LJ ;
CORONADO, EB ;
JACOBS, S ;
KULL, FC ;
ALLRED, DC ;
OSBORNE, CK .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) :1418-1423
[7]   Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer [J].
Baron-Hay, S ;
Boyle, F ;
Ferrier, A ;
Scott, C .
CLINICAL CANCER RESEARCH, 2004, 10 (05) :1796-1806
[8]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[9]   The igf-1 receptor in cancer biology [J].
Baserga, R ;
Peruzzi, F ;
Reiss, K .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (06) :873-877
[10]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348